Earnings
Home›Earnings›Previews›Medtronic and Danaher show contrasting momentum in hea…
Medtronic and Danaher show contrasting momentum in healthcare recovery
Medtronic posted fiscal Q4 revenue of $9.8 billion, and cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth.
Healthcare investors are seeing signs of recovery across parts of the medical device and life sciences sector, but the drivers differ, with Medtronic (NYSE: MDT) leaning on product and execution progress and Danaher (NYSE: DHR) tied more to improving customer spending in life sciences, according to Yahoo Finance.
Medtronic reported fiscal Q4 revenue of $9.8 billion, up 9.9% as reported and 6.6% on an organic basis, and full-year 2026 revenue of $36.4 billion with adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. The outlet said the company’s turnaround is shifting away from being dominated by cost controls, with newer growth platforms contributing more meaningfully to revenue.
Yahoo Finance also highlighted that Medtronic’s cardiac segment is emerging as a key growth driver. Cardiac Ablation Solutions revenue rose 78% globally, including 124% growth in the U.S., and the article notes cardiac devices are among the company’s highest-margin and fastest-growing businesses.
For Danaher, the recovery story depends more on improving customer spending in its Life Sciences business, the outlet said. It pointed to bioprocessing performance, where bioprocessing orders grew in the mid-teens in the quarter even as bioprocessing revenue was affected by customer project timings, and the company indicated that a little over $100 million of revenue shifted into next year.